Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 Injection in Type 2 Diabetes Mellitus (Phase II)
CTR20220751Phase 2Completed
- Sponsor
- Chengdu Tianshizhen Biotechnology
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GX-G6 in type 2 diabetes mellitus (T2DM), sponsored by Chengdu Tianshizhen Biotechnology. Started Apr 2022; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220751.